PKP2-ACM
Clinical trials for PKP2-ACM explained in plain language.
Never miss a new study
Get alerted when new PKP2-ACM trials appear
Sign up with your email to follow new studies for PKP2-ACM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human test of gene therapy for inherited heart disease
Disease control OngoingThis is a first-in-human study to test the safety and early effectiveness of a new gene therapy called LX2020. It is for adults with a specific genetic form of arrhythmogenic cardiomyopathy, a heart condition that can cause dangerous irregular heartbeats. The therapy is given thr…
Matched conditions: PKP2-ACM
Phase: PHASE1, PHASE2 • Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Scientists track patients for years after pioneering heart gene therapy
Disease control ENROLLING_BY_INVITATIONThis study is a long-term follow-up for up to 10 patients who previously received an experimental gene therapy (LX2020) for a genetic heart muscle disease. The main goal is to monitor their health for four more years to check for any long-term side effects. No new treatment is gi…
Matched conditions: PKP2-ACM
Sponsor: Lexeo Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC